Richard G. Everson, MD
Specialty
Institutional Affiliation
Languages
Education
Fellowship
Internship
Degree
Residency
Board Certification
Contact Information
Phone
Clinical Interests
Scientific Interests
Dr. Richard Everson's research is focused on:
- Clinical trials for patients with central nervous system tumors
- Evaluating the makeup of individual patient tumors including next generation sequencing to identify targetable mutations (by both targeted therapies and immunotherapy) establishing treatment models (cell lines, avatars) and using flow cytometry and cytoff to understand the immune cell populations within a tumor
- Developing next-generation immunotherapy treatments included engineered T-cell therapies for cancers in the central nervous system
- Understanding the causes of, and determining treatments for, tumor genetic syndromes such as neurofibromatosis and schwannomatosis
Highlighted Publications
Al-Holou WN, Hodges TR, Everson RG, Freeman J, Zhou S, Suki D, Rao G, Ferguson SD, Heimberger AB, McCutcheon IE, Prabhu SS, Lang FF, Weinberg JS, Wildrick DM, Sawaya R. Perilesional Resection of Glioblastoma Is Independently Associated With Improved Outcomes. Neurosurgery. 2019 Feb 25. pii: nyz008. doi: 10.1093/neuros/nyz008. [Epub ahead of print]
Yao J, Chakhoyan A, Nathanson DA, Yong WH, Salamon N, Raymond C, Mareninov S, Lai A, Nghiemphu PL, Prins RM, Pope WB, Everson RG, Liau LM, Cloughesy TF, Ellingson BM. Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. Neuro Oncol. 2019 May 4. pii: noz078. doi: 10.1093/neuonc/noz078. [Epub ahead of print]
Everson RG, Hashimoto Y, Freeman JL, Hodges TR, Huse J, Zhou S, Xiu J, Spetzler D, Sanai N, Kim L, Kesari S, Brenner A, De Monte F, Heimberger A, Raza SM. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design. J Neurooncol. 2018 Sep;139(2):469-478. doi: 10.1007/s11060-018-2891-8. Epub 2018 May 30.
Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017 Jun 1;19(6):796-807. doi: 10.1093/neuonc/now287.
Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10220-10225. doi: 10.1073/pnas.1706689114. Epub 2017 Sep 5.